CMS recalculates Medicare Advantage stars after Clover lawsuit loss, but not a freebie for plans
CMS will voluntarily recalculate 2027 Medicare Advantage Quality Bonus Payment star ratings for certain contracts after a court loss tied to Clover Health’s challenge to CMS’s star methodology. CMS said it will use only data it has explicit legal permission to collect and remove challenged measures. TD Cowen said average star changes for other insurers are limited. Clover previously said the 4-to-3.5 drop cost about $120 million in bonuses.
How this was made
The 30-second read
Why it matters
CMS is now voluntarily recalculating 2027 QBP ratings for certain MA contracts, removing measures based on explicit data-permission under the law. The article frames this as not delivering an across-the-board star boost, while still leaving room for further legal challenges.
Market read
This is a policy-driven earnings-risk catalyst for MA insurers because star ratings drive bonuses and competitive bid advantages; however, the memo suggests limited industry-wide uplift beyond Clover.
What to watch
Legal risk remains: CMS could still appeal the underlying decision, and insurers may time further challenges around the October 2027 star release.
Background
Clover sued CMS in November after its largest MA plan’s star rating fell from 4 to 3.5, alleging CMS used improper measures; a Georgia federal judge ordered a Clover-only recalculation in late May.
Ticker impact
CMS is recalculating 2026 Medicare Advantage stars after a court loss tied to Clover’s methodology challenge, affecting Clover’s 2027 Quality Bonus Payment ratings.
Near-term sentiment likely mixed: relief that CMS removed challenged measures, but limited upside versus what a broader extrapolation could have delivered.
The article states CMS will rerun contracts without the disputed measures for Clover, yet for other plans it appears only certain measures are removed, limiting read-across benefits.
Market effects
Medicare Advantage star/QBP methodology is destabilized, increasing the probability of additional insurer litigation and ongoing recalculation risk.
Primarily US healthcare/managed care equities; limited direct regional spillover beyond US MA participants.
Low—policy-driven US reimbursement mechanics with limited direct global linkage.
Counterpoint
The recalculation may be less market-moving than feared because CMS is not applying the Clover criteria broadly; upside for most insurers could be smaller than bulls hoped.
Key entities
- regulatorCMS
Voluntarily recalculating 2027 Quality Bonus Payment (QBP) ratings for certain Medicare Advantage contracts after a court decision.
- insurerClover Health
Plaintiff in the lawsuit; its star rating was ordered recalculated without disputed measures.
- analyst_firmTD Cowen
Provided estimates on potential star-score movement and interpreted CMS’s memo as conceding some data-source arguments while contesting others.
